Arvinas Inc.
5 Science Park
395 Winchester Ave
New Haven
Connecticut
06511
United States
Website: https://www.arvinas.com/
About Arvinas Inc.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
QUALITY BENEFITS
Designed with health and wellness in mind, employees and their families are eligible for:
- Medical, dental, and vision options, including a generous company contribution into an HSA
- Paid maternity and paternity leave
- FSA, HSA, Healthcare, and Dependent Care accounts
- Company provided life insurance and short/long-term disability coverage
- Additional voluntary benefits including critical illness, hospital care and more
COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:
- Competitive salaries and an annual incentive program
- 401K matching program with immediate vesting
- Eligibility for long-term equity incentives upon hire and annually
TIME OFF
We believe it’s important to relax, unwind and enjoy life’s moments:
- Paid vacation
- A year-end office closure
- Observed company holidays
- Paid sabbatical upon 5 years’ tenure
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
Working at Arvinas
116 articles about Arvinas Inc.
-
Arvinas Appoints Dr. John Houston As President Of Research And Development And Chief Scientific Officer
1/5/2017
-
Arvinas Presents Data On Oral Estrogen Receptor PROTAC Degrader At 2016 San Antonio Breast Cancer Symposium
12/9/2016
-
Arvinas Collaborators Present Data On BET PROTAC Degraders At 2016 American Society of Hematology Annual Meeting
12/6/2016
-
Arvinas Presents Data On Its BET PROTAC Degraders At 2016 European Organization for Research and Treatment of Cancer-NCI-AACR Symposium
11/29/2016
-
Arvinas Publishes First Peer-Reviewed, In Vivo Data From Its Proprietary PROTAC Technology
6/7/2016
-
Arvinas To Present Data At The 2016 AACR Annual Meeting
4/14/2016
-
Arvinas Appoints Angela Shen As Chief Medical Officer
3/2/2016
-
Arvinas Presents Data At The 2015 American Society of Hematology Annual Meeting
12/3/2015
-
Arvinas Secures $41.6 Million Series B Financing - Appoints New Board Members
10/21/2015
-
Arvinas Inks $300 Million Deal With Genentech Over Protein Degradation Technology
10/2/2015
-
Arvinas Appoints Robert Kleinfield As Chief Development Officer
9/23/2015
-
Arvinas Publishes First Peer-Reviewed Paper On Its Proprietary PROTAC Technology
6/5/2015
-
Arvinas Strikes $434 Million Collaboration with Merck & Co. to Continue Thriving in Connecticut
4/8/2015
-
Arvinas Appoints Manuel Litchman As President And Chief Executive Officer
1/12/2015
-
Arvinas Hires Jim Winkler As Chief Scientific Officer
2/10/2014
-
Yale University Spinout Arvinas Lands $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
9/27/2013